Bringing an institutional investor's lens to women's health.

For decades, women's health remained largely absent from mainstream investment frameworks—not because the healthcare needs were small, but because the science, data, markets and capital structures required to make the opportunity visible were underdeveloped.

That is now changing. Scientific progress, new diagnostics and therapeutics, demographic change, growing commercial evidence and increasing investor attention are bringing previously overlooked opportunities into view.

Drawing on her institutional-investment experience and the research behind The Billion Dollar Blindspot, Maryann explains what is changing and what investors need to understand before the opportunity becomes consensus.

Growing interest does not automatically create an investable portfolio. Women's health spans different clinical areas, technologies, stages, geographies and risk profiles, while much of the specialist expertise remains distributed across a fragmented manager landscape.

Maryann brings an institutional allocator's perspective to the practical question of participation. She explores why specialist expertise matters, how managers and opportunities should be evaluated, where diversification is required and what governance and investment infrastructure are needed to move from thematic interest to disciplined allocation.

Artificial intelligence is expanding what may be possible across diagnostics, drug development, clinical decision-making, patient identification and more personalised models of care.

But the intersection is not automatically investable. Success depends on representative data, clinical validation, regulatory pathways, reimbursement, workflow integration and sustainable business models.

Maryann examines where Women's Health and Healthcare AI genuinely intersect, where investment opportunities may emerge and how investors can distinguish meaningful healthcare innovation from technology-led enthusiasm.